Bioeq IP AG is a Swiss biopharmaceutical joint venture between the leading Polish pharmaceutical group Polpharma and the Strüngmann family’s investment company. Bioeq licenses, develops and commercializes biological successor products of successful biopharmaceuticals, called biosimilars. FYB201 is currently the most advanced biosimilar program of Bioeq. The clinical studies and registration are conducted by a subsidiary, Bi...
Bioeq IP AG is a Swiss biopharmaceutical joint venture between the leading Polish pharmaceutical group Polpharma and the Strüngmann family’s investment company. Bioeq licenses, develops and commercializes biological successor products of successful biopharmaceuticals, called biosimilars. FYB201 is currently the most advanced biosimilar program of Bioeq. The clinical studies and registration are conducted by a subsidiary, Bioeq GmbH based in Holzkirchen, Germany, on behalf of Bioeq IP AG.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.